Article

L370F and Y537S ESR1 mutations determine distinct endocrine therapy sensitivities and metabolic vulnerabilities that define new opportunities for synergistic therapeutic combinations

2026-06-02

Abstract excerpt

<title>Abstract</title> <p> <bold>Background.</bold> Somatic mutations in the <italic>ESR1</italic> gene encoding estrogen receptor α (ERα) are major drivers of resistance to endocrine therapy (ET) and CDK4/6 inhibitors (CDK4/6in) in ERα+/HER2− advanced breast cancer (ABC). While clinical and preclinical efforts have largely focused on recurrent ERα ligand-binding domain hotspot mutations, the functional and...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 7a1ad691-d329-5f22-9d6c-f0c3ab2821a1
DOI: 10.21203/rs.3.rs-9781236/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

L370F and Y537S ESR1 mutations determine distinct endocrine therapy sensitivities and metabolic vulnerabilities that define new opportunities for synergistic therapeutic combinationsDOI 10.21203/rs.3.rs-9781236/v1Read

Targeting Unique Ligand Binding Domain Structural Features Downregulates DKK1 in Y537S ESR1 Mutant Breast Cancer CellsSemantic proximity Read

ESR1-Activating Mutations Confer Metabolic Vulnerabilities in ER+ Breast Cancer.Semantic proximity Read

The natural L370F ERα Variant Confers Endocrine Resistance and Sensitivity to ATRA in Metastatic Breast Cancer CellsSemantic proximity Read

Estrogen Receptor Alpha Mutations, Truncations, Heterodimers, and Therapies.Semantic proximity Read

Mutation site and context dependent effects of ESR1 mutation in genome-edited breast cancer cell models.Semantic proximity Read

ESR1 mutations and therapeutic resistance in metastatic breast cancer: progress and remaining challenges.Semantic proximity Read

The natural L370F ERα variant confers endocrine resistance and sensitivity to ATRA in metastatic breast cancer cells.Semantic proximity Read

ESR1 mutation as an emerging clinical biomarker in metastatic hormone receptor-positive breast cancer.Semantic proximity Read

Genome engineering for estrogen receptor mutations reveals differential responses to anti-estrogens and new prognostic gene signatures for breast cancer.Semantic proximity Read

The ESR1 Mutations: From Bedside to Bench to Bedside.Semantic proximity Read

Endocrine resistance in breast cancer--An overview and update.Semantic proximity Read